These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24451411)

  • 41. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
    Rossi D; Terzi-di-Bergamo L; De Paoli L; Cerri M; Ghilardi G; Chiarenza A; Bulian P; Visco C; Mauro FR; Morabito F; Cortelezzi A; Zaja F; Forconi F; Laurenti L; Del Giudice I; Gentile M; Vincelli I; Motta M; Coscia M; Rigolin GM; Tedeschi A; Neri A; Marasca R; Perbellini O; Moreno C; Del Poeta G; Massaia M; Zinzani PL; Montillo M; Cuneo A; Gattei V; Foà R; Gaidano G
    Blood; 2015 Oct; 126(16):1921-4. PubMed ID: 26276669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Molecular cytogenetic characteristics of chronic lymphocytic leukemia].
    Xu W; Li JY; Pan JL; Qiu HR; Shen YF; Xiao B; Chen LJ; Wu YF; Sheng RL; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):349-52. PubMed ID: 17044998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
    Gohil SH; Maciocia N; Patrick P; Roberts T; Counsell N; Smith P; Clifton-Hadley L; Cwynarski K; Pettitt A; Nathwani AC
    Leuk Lymphoma; 2018 Jul; 59(7):1730-1733. PubMed ID: 29164978
    [No Abstract]   [Full Text] [Related]  

  • 44. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
    Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia.
    Park TS; Cheong JW; Song J; Choi JR
    Leuk Res; 2009 Jul; 33(7):1001-4. PubMed ID: 19155067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of chronic lymphocytic leukaemia incidence in Germany and of patients ineligible for standard chemotherapy.
    Eisemann N; Schnoor M; Katalinic A
    Hematol Oncol; 2016 Jun; 34(2):93-101. PubMed ID: 25757806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
    Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
    Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
    Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki AB; Koziner B; Chanan-Khan AA; Seymour JF; Gribben J; Itri LM; Rai KR
    J Clin Oncol; 2009 Nov; 27(31):5208-12. PubMed ID: 19738118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
    Mato AR; Roeker LE; Allan JN; Pagel JM; Brander DM; Hill BT; Cheson BD; Furman RR; Lamanna N; Tam CS; Handunnetti S; Jacobs R; Lansigan F; Bhavsar E; Barr PM; Shadman M; Skarbnik AP; Goy A; Beach DF; Svoboda J; Pu JJ; Sehgal AR; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Rhodes J; Ujjani CS; Nabhan C
    Am J Hematol; 2018 Nov; 93(11):1394-1401. PubMed ID: 30132965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
    Chapiro E; Lesty C; Gabillaud C; Durot E; Bouzy S; Armand M; Le Garff-Tavernier M; Bougacha N; Struski S; Bidet A; Laharanne E; Barin C; Veronese L; Prié N; Eclache V; Gaillard B; Michaux L; Lefebvre C; Gaillard JB; Terré C; Penther D; Bastard C; Nadal N; Fert-Ferrer S; Auger N; Godon C; Sutton L; Tournilhac O; Susin SA; Nguyen-Khac F;
    Am J Hematol; 2018 Mar; 93(3):375-382. PubMed ID: 29194741
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
    Puła B; Długosz-Danecka M; Salomon-Perzyński A; Szymczyk A; Subocz E; Budziszewska BK; Rybka J; Gil L; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Zaucha JM; Osowiecki M; Piszczek W; Steckiewicz P; Szukalski Ł; Hus M; Lech-Marańda E; Jurczak W; Jamroziak K
    Adv Med Sci; 2020 Sep; 65(2):371-377. PubMed ID: 32659728
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Gentile M; Shanafelt TD; Reda G; Mauro FR; Zirlik K; Ciolli S; Laurenti L; Del Principe MI; Rossi D; Di Renzo N; Molica S; Angrilli F; Coscia M; Chiarenza A; Giordano A; Cutrona G; Chaffee KG; Parikh SA; Uccello G; Innocenti I; Tripepi G; D'Arrigo G; Vigna E; Recchia AG; Herishanu Y; Shvidel L; Tadmor T; Cortelezzi A; Del Poeta G; Gaidano G; Di Raimondo F; Neri A; Ferrarini M; Foà R; Polliack A; Morabito F
    Leukemia; 2018 Aug; 32(8):1869-1873. PubMed ID: 29588545
    [No Abstract]   [Full Text] [Related]  

  • 56. Clonal evolution in patients with chronic lymphocytic leukemia.
    Loscertales J; Arranz E; Sanz MA; Blas C; Gil-Fernández JJ; Burgaleta C; Alegre A
    Leuk Lymphoma; 2010 Jun; 51(6):1142-3. PubMed ID: 20443678
    [No Abstract]   [Full Text] [Related]  

  • 57. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.
    Molica S; Giannarelli D; Mirabelli R; Levato L; Shanafelt TD
    Leuk Lymphoma; 2019 Jul; 60(7):1644-1649. PubMed ID: 30516079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.
    Bowen DA; Call TG; Jenkins GD; Zent CS; Schwager SM; Van Dyke DL; Jelinek DF; Kay NE; Shanafelt TD
    Leuk Lymphoma; 2007 Dec; 48(12):2412-7. PubMed ID: 18067017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
    Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
    Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.